Antipsychotics

Vermont Governor Shumlin recently suggested a change to state law that would accelerate the process under which a person could be forced to take antipsychotic drugs against her will. The House Human Services Committee reviewed this proposal and I was asked to testify. What follows are my comments.

An important study was headlined on MIA this week. The study examined the effectiveness of cognitive behavioral therapy (CBT) to treat the symptoms of people labeled with a diagnosis of schizophrenia and related conditions who had elected to not take neuroleptic drugs.

A new study, published in BMJ Open-Access this week, found a significant link between the level of air pollution in a community and the mental health of the children living there. After controlling for socio-economic status and other potential variables, researchers in Sweden discovered a strong association between the concentration of air pollution in a neighborhood and the amount of ‘antipsychotic’ and psychiatric drugs prescribed to children. The link remained strong even at pollution levels well below half of what is considered acceptable by the World Health Organization (WHO).

Martin Harrow and Thomas Jobe have a new article coming out in Schizophrenia Bulletin that I wish would be read by everyone in our society with an interest in “mental health.” Harrow and Jobe, who conducted the best study of long-term schizophrenia outcomes that has ever been done, do not present new data in this article, but rather discuss the central question raised by their research: Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Or does it hinder it?

Mixed-Methods study explores the experiences of antipsychotic discontinuation among service users.

The safety of our children is a sacred obligation we strive to preserve. Anything or anyone that harms them becomes the object of our...

The case of “Beth” depicts, almost innocently, the trials and tribulations of a well-adjusted, talented 15-year-old who developed depression, paranoia, panic attacks, and self-injurious and homicidal behavior, and “bipolar disorder” after being prescribed antidepressants, and then antipsychotics. After Beth decided - on her own - to discontinue psychotropic medications in favor of hormone therapy, she remained free of psychiatric symptoms.

New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”

Revealing the false information provided about psychiatry should cause any thinking person, patient, thought-leader or politician to wonder: “how many otherwise normal or potentially curable people over the last half century of psych drug propaganda have actually been mis-labeled as mentally ill (and then mis-treated) and sent down the convoluted path of therapeutic misadventures – heading toward oblivion?”

Two pieces of research have been published over the last two years that should prompt a major reorientation of the treatment of schizophrenia and psychosis, and a fundamental reappraisal of the use of antipsychotic drugs in general. Put together, these studies suggest that the standard approach to treating serious mental health problems may cause more harm than good. Long-term treatment with antipsychotic drugs has adverse effects on the brain, and may impair rather than improve chances of recovery for some. Many people ask me how the psychiatric profession has responded to this data. Surely, they think, it must have stimulated a major debate within the profession, and some critical reflection about why it took so long to recognise these worrying effects? Sadly, this does not appear to be happening.

Ten years after being fired for taking a mental health leave after the Virginia Tech massacre, I was diagnosed as "schizophrenic" and involuntarily committed to a hospital. Now I have a job and a life, but I'm still forced to take drugs and report to a social worker.

In 1972, prisoners at Holmesburg Prison in Philadelphia were paid $3 to have their eyes held open with clamps and hooks while Johnson & Johnson's baby shampoo was dropped into them. In 2011, mothers of newborns were arrested when their babies tested positive for exposure to cannabis, a false result caused by the use of Johnson & Johnson’s Head-to-Toe Foaming Baby Wash. Young men have undergone mastectomies to remove breasts grown as a result of Johnson & Johnson antipsychotics, which were used as a result of Johnson & Johnson's criminal promotion of its drugs for off-label purposes. And now, Johnson & Johnson has announced the removal of carcinogenic chemicals from their No More Tears baby shampoo.

The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...

This week, MIA highlighted a recently published study of the four most commonly prescribed neurolpetics. As noted in the post, the major outcome was that these drugs were not found to be effective or safe. This important study, co-authored by Dilip Jeste the current president of the American Psychiatric Association, is worth reviewing in greater detail.

A former pharma executive has broken ranks with the industry in a new book by reporting how multiple psychiatrists, schools, and his desperate hopes pressed him to allow higher and higher doses of antipsychotic medications. The result: his 15-year-old son's death from Seroquel.

Preface The World Health Organization has repeatedly found that people diagnosed with schizophrenia in the U.S. and other developed countries fare much worse than schizophrenia...

The National Council for Behavioral Health has released a new pamphlet titled “Guide to Long-Acting Medications for Providers and Organizations.” By downplaying some aspects of the available science, the pamphlet implicitly acts as a promotional tool for the pharmaceutical industry.

Researchers find that support and self-care were helpful for users during discontinuation, but that mental health professionals were not very helpful.

"My studies in this area lead me to a very uncomfortable conclusion: Our citizens would be far better off if we removed all the psychotropic drugs from the market, as doctors are unable to handle them. It is inescapable that their availability creates more harm than good." - Peter Gøtzsche, MD; Co-founder of the Cochrane Collaboration

Association found between long-term antipsychotic use and poorer performance on cognitive tasks in adults diagnosed with ‘schizophrenia.’

A recent paper published in Schizophrenia Bulletin reported on a meta-analysis of antipsychotic drugs which found that a significant number of people do not experience a remission of psychotic symptoms. The evidence base suggests that it is time for us to reappraise the effectiveness of these drugs and shift our practice patterns accordingly.

Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.

In a systematic literature review, researchers from Canada and Japan found that the antipsychotic aripiprazole (Abilify) was significantly and causally related to increased increased...

People who take antipsychotic medications experience many side effects which have "major disruptive impact on their lives," according to research in the Journal of Mental Health Nursing.

The FDA has rejected the drug/device combination designed to monitor patient adherence with Abilify from Otsuka Pharmaceutical and Proteus Digital Health. Just last week...